RNA

RNA is trading as a high-conviction **Special Situation**, pinned near all-time highs ($72.89) due to the pending **Novartis acquisition** (agreed Oct 2025) and the imminent **Atrium Therapeutics spinoff**. The 'Perfect Stack' and 'Alpha Male' signals reflect the market's certainty in deal consummation, effectively decoupling the stock from the broader 'Goldilocks' macro noise. The elevated volume (1.7x) is structural, driven by institutional re-positioning ahead of the spinoff record date.